Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Arcus Biosciences nets $128mm in IPO

Executive Summary

Arcus Biosciences Inc. (cancer immunotherapies) netted $128mm through its initial public offering of 9.2mm common shares (including the overallotment) priced at $15; the company had originally intended to sell 7.1mm shares at a range of $13-15.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies